BAT4406F

DRUG2 trials

Sponsors

Bio-Thera Solutions

Conditions

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Neuromyelitis Optica Spectrum Disorders

Phase 1

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

CompletedNCT04146285

Bio-Thera SolutionsNeuromyelitis Optica Spectrum Disorders

Start: 2020-09-01End: 2023-12-25Updated: 2025-07-10

Phase 2

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

RecruitingNCT07499700

Bio-Thera SolutionsFocal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD)

Start: 2025-10-26End: 2030-11-26Target: 192Updated: 2026-04-03

Related Papers

First‐in‐Human Study of <scp>BAT4406F</scp>, an <scp>ADCC</scp>‐Enhanced Fully Humanized Anti‐<scp>CD20</scp> Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders

CNS Neuroscience & Therapeutics2024-11-014 citations